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Abstract. Rates of tuberculosis (TB) in Africa are highest among people infected with HIV. Searching for additional
risk factors in a cohort of HIV-infected Ugandan adults, we previously found that a type 2 cytokine bias and eosinophilia
were associated with progression to active TB. A possible role for helminth infection was assessed in this study. We
analyzed TB incidence in 462 members of this cohort who were screened for filarial infections, gastrointestinal nema-
todes, and schistosomiasis. Progression to TB was not associated with gastrointestinal nematodes (rate ratio [RR], 1.18;
confidence intervals [CIs], 0.66–2.10) or Mansonella perstans (RR, 0.42; CI, 0.13–1.34). A weak association between
Schistosoma mansoni infection and TB was found (RR, 1.42; CI, 0.86–2.34); after adjusting for potential explanatory
variables and using more stringent diagnostic criteria, the association was strengthened (RR, 2.31; 1.00–5.33). This
analysis suggests an effect of S. mansoni infection on progression to active TB among HIV-1–infected Ugandans.
INTRODUCTION
One major consequence of the HIV epidemic has been the
increased rate of tuberculosis (TB) in HIV-infected subjects.1
Reactivation of latent TB occurs faster in HIV infection, rap-
idly progressive TB disease is more common, and case fatality
rates are higher than in HIV-uninfected subjects. It is the
major cause of death in HIV-infected Africans.2 Further-
more, the effect of TB on viral replication may aggravate the
underlying immunosuppression and accelerate HIV disease
progression in infected subjects.3,4 The World Health Orga-
nization recommends isoniazid preventive therapy for all
HIV-infected subjects with evidence of latent TB infection5;
however, there are significant difficulties in identifying these
subjects, the duration of efficacy may be short, and the cost-
effectiveness of this strategy is debatable.6,7 Establishing
other risk factors for progression to active TB among HIV-
infected subjects may lead to better preventive strategies in
this high-risk population, for whom antiretroviral therapy has
not yet become widely available. Attempts to characterize the
immunologic profile of susceptibility to disease have consid-
ered both the type 1/type 2 model of immune responses to
infection and the role of immunoregulatory cytokines in the
response to mycobacteria. We previously showed, in a cohort
of HIV-infected adults in Uganda, that eosinophilia, associ-
ated with a type 2 cytokine profile, was the strongest predictor
of subsequent progression to active TB.8 Helminth infections
are well-recognized inducers of a type 2 immune response and
were associated with eosinophilia in this cohort.9,10 As part of
a larger study of the impact of helminth infection on HIV
disease progression that has already been reported,9 we as-
sessed the role of helminth infection as a risk factor for pro-
gression to active TB in HIV-infected adults in Uganda.
MATERIALS AND METHODS
Study subjects. Study subjects, who attend either The
AIDS Support Organization (TASO) clinic or the Uganda
Virus Research Institute (UVRI) clinic in Entebbe, were
members of the Entebbe cohort (EC). This prospective co-
hort of HIV-infected adults was established by the UK Medi-
cal Research Council (MRC) program on AIDS in Uganda in
1995,11 and recruitment to the cohort is ongoing. Participants
(∼2,300 between October 1995 and March 2002) attend rou-
tinely every 6 months and at additional interim visits if they
fall sick. Antiretroviral (ARV) drugs did not become widely
available to study participants until February 2003.
Worm study enrollment. All patients attending their rou-
tine EC appointment in February to July 2001 and February
to March 2002 were counseled and enrolled into this study
after providing written informed consent. A questionnaire
was completed, stool and blood samples were collected, and
albendazole 400 mg was provided to all subjects. Subjects
identified from their enrollment specimens as having Schisto-
soma mansoni were treated with praziquantel 40 mg/kg 1
month after enrollment.
Laboratory tests. Duplicate 41.7-mg Kato-Katz smears,12
modified formol-ether concentration, and charcoal culture for
Strongyloides were performed on all fecal specimens where
possible. Enzyme-linked immunosorbent assay (ELISA) for
circulating anodic antigen (CAA) of S. mansoni13 was per-
formed on serum samples to boost the limited diagnostic yield
of a single stool sample and also to avoid the possible con-
founding effect of immunosuppression on fecal egg excre-
tion.14 Subjects were diagnosed as infected with S. mansoni if
either Kato-Katz method or CAA ELISA was positive. Mi-
crofilaria were diagnosed using a modified Knott concentra-
tion method described for hyperproteinemic patients.15 The
above techniques are described in detail elsewhere.9,16
Blood samples were examined for CD4+ T-lymphocyte
count by FACScount (Becton Dickinson, Erembodegen,
Belgium).
Diagnosis of TB and analysis of TB incidence rates. Data
on TB diagnosis and treatment have been collected system-
atically within the cohort from August 1997. An operational
study assessed the implementation of isoniazid prophylaxis in
this cohort between October 1998 and November 19996; tu-
berculin skin tests (TSTs; 5 IU of purified protein derivative
[PPD] given intradermally using the Mantoux technique)
were performed on 1,597 subjects recruited since 1995, of
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whom 74 subjects received 6 months of isoniazid therapy. The
National TB Control Program did not consider the results of
this study to be sufficient to recommend ongoing implemen-
tation of isoniazid preventive therapy (IPT) in this popula-
tion, so IPT has not been provided since 1999, but tuberculin
skin testing on new EC recruits has continued.
Figure 1 shows the time-course for analysis of TB incidence
in this cohort. Subjects recruited into EC before August 1997
(of whom some may have developed TB before this date)
were excluded from the study. Subjects with a history of TB
before recruitment to the EC were also excluded. An assump-
tion was made that those diagnosed as having helminths at
enrollment into this study had helminth infection over the
previous period that they had been in the EC.9
During follow-up, participants with evidence of active TB
were studied and treated. Active TB was classified as follows:
1) confirmed, positive culture for Mycobacterium spp.; 2)
probable, symptoms and signs of TB, with either clinical re-
sponse and weight gain  2 kg after treatment of TB, or
microscopy positive for acid-fast bacilli, but without a positive
culture result; 3) possible, symptoms and signs of TB but no
information regarding response to treatment; and 4) TB di-
agnosed elsewhere, details of studies not available. In subse-
quent analyses, unless otherwise stated, TB was defined as
any case classified above as 1), 2), or 3).
Follow-up times (from EC recruitment until 18 months af-
ter Worm study enrollment) were censored if the participant
developed TB, died, defaulted, started isoniazid preventive
therapy or ARV therapy, or were treated for the helminth
species in question. As different helminth species were
treated (or not) at different time-points, some analyses were
based on shorter follow-up periods, depending on the hel-
minth under scrutiny (see below). Crude and adjusted rate
ratios (RRs) and confidence intervals (CIs) were estimated
using Cox proportional hazard regression. P values for ad-
justed RRs were estimated using the likelihood ratio test.
Information on socio-economic factors and risk factors for
helminth exposure was collected in the Worm study.9 These
variables were also tested against TB incidence by univariate
analyses. Stepwise regression analysis identified variables that
were independently associated (P < 0.20) with both helminth
status and TB incidence; these were included in the final
model, along with age, sex, CD4+ count at EC recruitment,
other helminths, and Bacille Calmette-Ave´rin (BCG) status
(recorded as presence of a BCG scar).
Ethical approval. Ethical clearance for the study was
granted by the Uganda National Council for Science and
Technology; the science and ethics committee for UVRI; and
the ethics committee of the London School of Hygiene and
Tropical Medicine.
RESULTS
Tuberculosis in the EC. A total of 1,168 ARV-naïve sub-
jects were recruited to the EC between August 1997 and
March 2002. Median age at recruitment was 31 years (range,
17–66 years); 70% were female. CD4+ T-lymphocyte count at
recruitment was 200 cells/mm3 in 586 (48%) subjects, 500
cells/mm3 in 214 (18%) subjects, and missing in 8 (< 1%)
subjects. Forty-two percent were in World Health Organiza-
tion clinical stage 1 or 2.
One hundred forty-nine subjects (13%) had been treated
for TB before EC recruitment. These were excluded from sub-
sequent analyses of TB incidence. The isoniazid preventive
therapy study between 1998 and 1999 included 45 subjects who
joined the EC in or after August 1997 who received isoniazid.
These subjects were censored at the date of starting isoniazid.
TB diagnosis rates were analyzed between recruitment to
EC and 18 months after enrollment in the Worm study (Sep-
tember 2003). One hundred twenty-six subjects developed TB
during this time, with an incidence of 70 per 1,000 person-
years (CI, 59–84 per 1,000 person-years). TB incidence was
inversely associated with CD4+ count at EC recruitment
(compared with CD4+  200 cells/mm3: RR, 0.92; CI, 0.62–
1.37 for CD4+ 200–499 cells/mm3, P  0.70; RR, 0.48; CI,
0.28–0.81 for CD4+  500 cells/mm3, P  0.006) and with
World Health Organization clinical stage (RR, 1.8; CI, 1.38–
2.35 per advancing stage, P < 0.001).
A positive TST ( 5 mm) was present in 22% subjects at
recruitment and was strongly associated with progression to TB
(RR adjusted for CD4+ count 3.7; CI, 2.51–5.40; P < 0.001).
Mortality was lower in subjects diagnosed with TB during
this follow-up period (RR adjusted for age, sex, and CD4+
count  0.74; CI, 0.57–0.96; P  0.02).
Tuberculosis in Entebbe cohort subjects enrolled in the
Worm study. Four hundred sixty-two subjects were enrolled
in the Worm study between February 2001 and March 2002.
Of these, 39 had an incomplete screen for helminth infection;
after excluding these, 423 were included in subsequent analy-
ses. Seventy percent of the subjects were women. Only EC
FIGURE 1. Time-course for TB incidence analysis in the Entebbe Cohort (numbers exclude those with a previous history of TB).
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participants who had survived until 2001–2002 could be en-
rolled in the Worm study, so median CD4+ count at EC re-
cruitment was higher in those in the Worm study than in those
not enrolled (346 versus 137 cells/mm3; P < 0.0001).
Helminth prevalence in the Worm study was 54%, with S.
mansoni, hookworm, S. stercoralis, and M. perstans being the
principal species in this cohort. Details on diagnosis of, and
risk factors associated with, different helminths are provided
elsewhere.9,16
Forty-seven of these 423 subjects had a diagnosis of TB
before EC recruitment (Table 1). Of the remaining 376, 66
developed TB during the follow-up period (incidence 69 per
1,000 person-years; CI, 55–84 per 1,000 person-years).
S. mansoni and TB. Of 140 subjects with S. mansoni infec-
tions, 14 had a diagnosis of TB before EC recruitment (10%
versus 12% without S. mansoni, P  0.61).
There was no association between S. mansoni infection and
TST positivity (20% with S. mansoni versus 24% without S.
mansoni, P  0.40).
Antischistosomal treatment was given to infected subjects 1
month after Worm study enrollment; all subjects were cen-
sored at this date. Sixty-six subjects developed TB between
EC recruitment and this date (incidence 139 cases per 1,000
person-years; CI, 109–177 per 1,000 person-years). TB inci-
dence was slightly greater among S. mansoni–infected sub-
jects (RR, 1.42; P 0.17; Table 1). The RR was greater using
a stricter case definition of confirmed or probable TB diag-
noses only (RR, 1.82; CI, 1.06–3.10; P  0.03), and was
greater still if including only confirmed TB diagnoses (RR,
2.51; CI, 1.15–5.51; P  0.02).
The association was only slightly weakened by adjustment
for socio-economic factors and other potential explanatory
variables. Stepwise regression analysis identified only prox-
imity to Lake Victoria as independently associated with both
S. mansoni status and (inversely) with TB incidence; this was
included in the final model, along with age, sex, CD4+ count
at EC recruitment, other helminths, and BCG status. Using
this model, the association between S. mansoni and TB inci-
dence was only slightly weakened (adjusted RR, 1.35; CI,
0.80–2.30; P 0.27; Figure 2A; for confirmed or probable TB
diagnoses only: RR, 1.68; CI, 0.96–2.96; P  0.07; for con-
firmed TB diagnoses: RR, 2.31; CI, 1.00–5.33; P  0.05; Fig-
ure 2B).
Incidence rates were slightly but not statistically higher in
those with the highest intensity S. mansoni infections (223 per
1,000 person-years in those with >100 eggs per gram of feces
[epg] versus 171 per 1,000 person-years in S. mansoni–
infected subjects with <100 epg; RR, 1.41; P  0.47).
M. perstans and TB. Of 34 subjects with M. perstans infec-
tions, only 1 had a diagnosis of TB before EC recruitment
(3% versus 12% without M. perstans, P  0.11).
M. perstans infection was associated with a reduced preva-
lence of positive TST responses (6% versus 25%, P  0.02).
No effective treatment was given to subjects infected with
M. perstans, so associations with TB incidence were analyzed
through to 18 months after Worm study enrollment. TB inci-
dence was slightly lower in M. perstans–infected subjects (31
per 1,000 person-years versus 74 per 1,000 person-years; RR,
0.42; P 0.14; Table 1). Multivariate analysis, including (for
this helminth) electricity supply and proximity to the lake,
along with age, sex, CD4+ count at EC recruitment, other
helminths, and BCG status, did not substantially change the
RR (adjusted RR, 0.41; P 0.14). Restricting the analysis to
probable or confirmed TB cases gave an adjusted RR of 0.32
(CI, 0.08–1.33; P  0.12) and to confirmed cases gave an
adjusted RR of 0.37 (CI, 0.05–2.80; P  0.34).
Gastrointestinal nematodes and TB. Of 132 subjects with
gastrointestinal (GI) nematode infections, 15 had a diagnosis
of TB before EC recruitment (11% versus 11% without GI
nematodes, P 0.91). There was no association between GI
nematode infection and positive TST responses (23% versus
23%, P  0.91).
Albendazole was given to all subjects at Worm study en-
rollment, so for the purposes of this analysis, all subjects were
censored at this time-point. Because some subjects were re-
cruited to the EC and enrolled in the Worm study at the same
TABLE 1
Baseline characteristics and TB incidence rate ratios according to helminth infection
S. mansoni GI nematodes M. perstans No helminths*
No. P† No. P† No. P† No.
Total 140 132 34 168
Previous TB 14 15 1 23
Total analysed‡ 126 83 33 139
Median CD4+ count at EC recruitment
(interquartile range)
371 (179–512) 0.92 365 (203–615) 0.96 436 (237–649) 0.31 362 (195–574)
WHO clinical stage 3 or 4 58 (46%) 0.10 30 (36%) 0.92 11 (33%) 0.40 45 (32%)
BCG scar (missing values) 77 (62%) 0.56 42 (53%) 0.60 20 (63%) 0.68 75 (54%)
3 1 1
TST  5 mm (missing values) 24 (20%) 0.40 19 (23%) 0.91 2 (6%) 0.02 35 (36%)
8 1 1 7
TB cases 25 17 3 20
Person-years 138 129 98 216
Incidence per 1000 person-years (CIs) 181 (123–168) 132 (82–213) 31 (10–95) 93 (60–144)
Rate ratio (RR) (CIs) 1.42 (0.86–2.34) 1.18 (0.66–2.10) 0.42 (0.13–1.34) –
Adjusted RR§ (CIs) 1.35 (0.80–2.30) 0.27 0.95 (0.50–1.80) 0.88 0.41 (0.13–1.33) 0.14 –
Confirmed TB cases 13 7 1 7
Adjusted RR (CIs) 2.31 (1.00–5.33) 0.05 0.83 (0.32–2.18) 0.34 0.37 (0.05–2.80) 0.71 –
* No helminth group presented for comparison, but significance tests and rate ratios are given for individual helminth species vs subjects without that particular helminth species; note that
many subjects were infected with multiple helminths.
† 2 for comparison of proportions, Wilcoxon rank-sum test for comparison of medians, and likelihood ratio test for rate ratios.
‡ For no helminth group and for GI nematode group, no. of subjects excludes those recruited to Entebbe cohort (EC) and enrolled in Worm study at the same visit.
§ Adjusted for age, sex, BCG status, recruitment log10 CD4
+ count, other helminth infections, and socioeconomic factors: for S. mansoni, walking distance from Lake Victoria; for GI nematodes,
electricity supply at home; for M. perstans, both.
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visit, subsequent analyses were restricted to 294 subjects who
were recruited to EC at least 6 months before Worm study
enrollment (and without a diagnosis of TB before EC recruit-
ment). There was no association between TB incidence and
GI nematode infection (132 per 1,000 person-years versus 109
per 1,000 person-years; RR, 1.18; P  0.59; Table 1). Multi-
variate analysis, including (for this helminth group) electricity
supply, along with age, sex, CD4+ count at EC recruitment,
other helminths, and BCG status, did not substantially change
the RR (adjusted RR, 0.95; P 0.88). Restricting the analysis
to probable or confirmed TB cases gave an adjusted RR of
0.99 (CI, 0.50–1.95; P 0.97) and to confirmed cases gave an
adjusted RR of 0.83 (CI, 0.32–2.18; P 0.71). No association
was seen between number of concurrent helminth infections
and TB incidence (data not shown).
DISCUSSION
In a cohort with a high incidence of TB, and prospective
data on TB incidence rates, we were unable to show a clear
association between helminth infection and progression to
active TB. Analysis according to helminth species (grouped
by phyla or superfamilies sharing similar life cycles or host
tissue locations) revealed some differences. For GI nema-
todes, a weak association seen in crude univariate analyses
was further weakened after adjusting for potential explana-
tory variables such as socio-economic factors and CD4+ T-
lymphocyte count. However, there was evidence for an asso-
ciation between S. mansoni infection and TB incidence; al-
though not statistically significant on crude analysis (the study
had > 75% power to detect a 2-fold difference in TB inci-
dence between those with and without S. mansoni), the asso-
ciation became stronger and statistically significant when
stricter criteria for TB diagnosis were used and only slightly
weaker after adjusting for potential explanatory variables.
Despite the limitations on assessing S. mansoni infection in-
tensity on the basis of a single stool sample, slightly higher TB
rates were seen in the subjects with the heaviest infections.
Studies in animal models of co-infection, as well as human
FIGURE 2. (A) Survival to active TB for individuals with and without S. mansoni infection. See Table 1 for statistical tests and explanatory
variables. (B) Survival to active TB for individuals with and without S. mansoni infection—confirmed TB cases only (N  13). See Table 1 for
statistical tests and explanatory variables.
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studies in vitro and in vivo, have indicated the suppression of
anti-mycobacterial immune responses in the presence of hel-
minth infection.17–24 Despite these data, evidence supporting
a role for helminths in accelerating progression to active TB
has not been subjected to systematic epidemiologic study. A
small hospital-based case-control study from Brazil found an
association between intestinal nematodes and tuberculosis,
but was subject to the potential biases inherent in such a study
design.25 We previously showed a strong association between
eosinophilia and progression to TB in this cohort. In sub-
group analyses, we also found an association between anti-
mycobacterial interleukin (IL)-5 responses and progression to
TB (in participants with a BCG scar) and IL-10 responses
and progression to TB (in subjects with a positive tuberculin
skin test response). Retrospective testing of stored sera for
Schistosoma-circulating antigen failed to implicate S. man-
soni.8,26 With more extensive screening for Schistosoma in-
fections in this study, we found evidence of a relationship.
Screening for intestinal nematodes and circulating filarial in-
fections, which are also strongly associated with eosinophil
count in this cohort,9 did not implicate these helminths in this
association.
Ethical considerations have generally prevented prospec-
tive studies of the effects of untreated helminth co-infection.
The current Worm study has attempted to deal with this prob-
lem with the assumption that infections diagnosed at enroll-
ment had been present when patients were initially recruited
to the EC. The (adult) age distribution of the cohort would
support this assumption because the well-established age-
prevalence distributions of the more common infections in
this population suggest that subjects are likely to have been
infected in childhood. Anti-schistosomal treatment was not
widely available before this study, and we already showed
supportive evidence for the chronicity of the other infec-
tions.8,9 We can also be confident that this assumption holds
for M. perstans, which was the least likely to have been
treated and for which the most follow-up time was available
(the majority of M. perstans–infected subjects remained in-
fected when re-screened 6 months after Worm study enroll-
ment9). This helminth was also most strongly associated with
eosinophilia.9 There was a weak inverse association between
this infection and TB incidence (the study had 75% power to
detect the difference as statistically significant at the 5%
level), despite an association with reduced tuberculin skin test
reactivity. This did not seem to be caused by less mycobac-
terial exposure in Mansonella-exposed subjects; the associa-
tion was, if anything, stronger after adjusting for socio-
economic and demographic variables. Mycobacterium-
specific immune responses, although skewed, were detected
as frequently in Mansonella-infected subjects.27,28 As we have
previously shown, it seems clear that helminth species vary in
their effects in co-infected subjects.9
We addressed the potential biases inherent in the retro-
spective study design. First, an excess mortality in helminth-
infected subjects could lead to an underestimate of a true
association by reducing the number of helminth-infected sub-
jects surviving to enrollment in the Worm study. However,
our previous analyses have shown that helminth infection is
not associated with more advanced HIV disease or increased
mortality in this cohort.9 Nor was diagnosis of TB in the
cohort as a whole associated with an increased mortality rate;
in fact, mortality was lower in subjects who were diagnosed
with TB (this could be explained by misclassification of
deaths from undiagnosed TB in the cohort—those with most
advanced disease may have succumbed to TB before a diag-
nosis could be made—or perhaps a protective effect of anti-
tuberculous therapy against other opportunistic infections).
Second, a true association between helminth infection and TB
could lead to the exclusion of helminth-infected subjects from
the analysis because of a history of TB before EC recruit-
ment. However, no association was found between helminth
infection and previous TB. Third, defective anti-mycobac-
terial immune responses in helminth-infected subjects might
lead to less classic presentations, and therefore underdiagno-
sis, of TB in these subjects. This explanation is unlikely be-
cause TB diagnosis was not based only on smear positivity.
Smear-negative and extra-pulmonary TB constituted a signifi-
cant proportion of diagnosed cases, and categorization by
strength of evidence for a diagnosis of TB strengthened the
association with S. mansoni and did not affect the results for
other helminths. Fourth, TB infection may be less common
among helminth-infected subjects, because of differences in
environmental exposures. As discussed above, however, ad-
justing for socio-economic variables did not unmask any as-
sociations; nor were TST responses less prevalent in hel-
minth-infected subjects, except in the case of M. perstans.
Finally, there was no association between BCG immunization
(as measured by the presence of a BCG scar) and helminth
infection,27 and inclusion of BCG status in the multivariate
analyses did not affect the RRs.
Several mechanisms could explain the association between
S. mansoni and TB progression, independent of type 2 cyto-
kine bias and eosinophilia. Enhanced production of cytokines
such as transforming growth factor- and IL-10, which have
been shown in human Schistosoma infection in our cohort and
others, has been associated with suppression of anti-
mycobacterial immunity.10,27,29–32 Immune activation is well
described in African subjects, is associated with active TB,
and may itself be driven by concurrent infections including
helminths.4,33–38 However, any effects of helminths on TB
progression may be mediated as much by influencing HIV-
induced immunopathology as by direct effects on anti-
mycobacterial immunity. The preserved immune status
shown in subjects with hookworm and Mansonella infections
in our cohort would support this argument.9,34,39
Helminth-induced modulation of anti-mycobacterial im-
mune responses may be quite different in other settings. Al-
though TB incidence is lower in HIV-negative populations, in
such patients, the cellular mechanisms by which helminths
could affect anti-mycobacterial immune responses are not ab-
rogated by CD4+ depletion and may be more easily shown.
Timing is important in polarization of the immune response,40
which may be set early, perhaps in utero.22 Current studies are
underway to establish the effect of maternal and early child-
hood helminth infection on anti-mycobacterial immune re-
sponses and subsequent incidence of TB to address this issue.
Finally, this analysis, added to published evidence from this
cohort and from other settings, questions the assumption that
all asymptomatic helminth infections are detrimental in HIV-
infected subjects.9,10,41 Placebo-controlled studies of treat-
ment of mild-moderate helminth infection and prospective
follow-up of TB incidence and HIV progression should be
encouraged.
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